Edition:
United States

Aurinia Pharmaceuticals Inc (AUP.TO)

AUP.TO on Toronto Stock Exchange

7.14CAD
18 Apr 2018
Change (% chg)

-- (--)
Prev Close
$7.14
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
47,795
52-wk High
$11.07
52-wk Low
$5.68

Chart for

About

Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead... (more)

Overall

Beta: 3.32
Market Cap(Mil.): $604.00
Shares Outstanding(Mil.): 84.05
Dividend: --
Yield (%): --

Financials

  AUP.TO Industry Sector
P/E (TTM): -- 200.91 33.50
EPS (TTM): -1.44 -- --
ROI: -61.35 -0.75 13.17
ROE: -70.20 -2.86 14.98

BRIEF-Aurinia Pharmaceuticals Reports Qtrly Loss Per Share ‍of $0.04​

* AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Mar 15 2018

BRIEF-Aurinia Pharmaceuticals Files For Mixed Shelf Of Up To $250 Mln

* AURINIA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $250 MILLION – SEC FILING Source text: [http://bit.ly/2CTvkK1] Further company coverage:

Jan 04 2018

BRIEF-Aurinia Pharmaceuticals Added To The Nasdaq Biotech Index

* AURINIA PHARMACEUTICALS ADDED TO THE NASDAQ BIOTECH INDEX Source text for Eikon: Further company coverage:

Dec 11 2017

BRIEF-Aurinia reports Q3 loss per share $0.16

* Aurinia reports third quarter 2017 financial results and provides operational highlights

Nov 14 2017

BRIEF-Robert Duggan reports 5.9 pct stake in Aurinia Pharmaceuticals - SEC filing‍​

* Robert Duggan reports 5.9 percent stake in Aurinia Pharmaceuticals Inc as on October 19, 2017 - SEC filing‍​

Oct 23 2017

BRIEF-Aurinia Pharmaceuticals plans to expand voclosoprin renal franchise

* Aurinia Pharmaceuticals Inc - ‍ plans to expand voclosoprin renal franchise to include focal segmental glomerulosclerosis and minimal change disease​

Oct 20 2017

Earnings vs. Estimates